蔡氏妇科消淤方联合重组人干扰素治疗宫颈人乳头瘤状病毒感染的疗效分析  

Effect analysis of CAI′s gynecological Xiaoyu prescription combined with recombinant human interferon in the treatment of cervical HPV infection

作　　者：姚秋雯 王隆卉[3] 景桂英 Yao Qiuwen;Wang Longhui;Jing Guiying(Department of Traditional Chinese Medicine,Shanghai Yangpu District Kongjiang Hospital,Shanghai 200093,China;不详)

机构地区：[1]上海市杨浦区控江医院中医科,200093 [2]上海市杨浦区控江医院病理科,200093 [3]上海市中医医院妇科

出　　处：《山西医药杂志》2021年第8期1246-1249,共4页Shanxi Medical Journal

摘　　要：目的探讨蔡氏妇科消淤方联合重组人干扰素在宫颈人乳头瘤状病毒(HPV)感染患者中的临床疗效。方法选择2018年2月至2020年1月宫颈HPV感染患者78例作为对象,随机数字法分为2组,各39例。对照组采用重组人干扰素治疗,观察组在对照组基础上联合蔡氏妇科消淤方治疗,3个月治疗后对患者完成6个月随访,比较2组证候积分、炎症因子水平、不良反应发生率、转阴率。结果观察组治疗后3个月尿频尿急、白带及黏液、月经不调、盆腔沉重感及痛经评分低于对照组(P<0.05);观察组治疗后3个月肿瘤坏死因子-α(TNF-α)、白细胞介素-2、6、17(IL-2、6、17)低于对照组(P<0.05);IL-10高于对照组(P<0.05);2组不良反应发生率及治疗后第1、3个月复发率差异无统计意义(P>0.05);观察组6个月复发率低于对照组(P<0.05);观察组治疗后低危病例数、高危病例数均低于对照组(P<0.05),即观察组治疗后低危、高危患者转阴率高于对照组(P<0.05)。结论蔡氏妇科消淤方联合重组人干扰素用于宫颈HPV感染患者中能降低证候积分,有助于降低炎症因子水平,降低患者治疗后复发率,且未增加不良反应发生率,值得推广应用。Objective To explore the clinical efficacy of CAI′s gynecological Xiaoyu prescription combined with recombinant human interferon in patients with cervical HPV infection.Methods 78 patients with cervical HPV infection from February 2018 to January 2020 were selected as subjects.By random number method,these patients were divided into two groups,each with 39 cases.The control group was treated with recombinant human interferon,and the observation group was treated with CAI′s gynecological Xiaoyu prescription on the basis of the control group.After 3 months of treatment,the patients were followed up for 6 months,and the two groups were compared with syndrome scores,inflammatory factor levels,and adverse reactions incidence rate,negative rate.Results The scores of frequent urination,leucorrhea and mucus,irregular menstruation,pelvic heaviness and dysmenorrhea in the observation group 3 months after treatment were lower than those of the control group(P<0.05);tumor necrosis factor-α(3 months after treatment in the observation group,TNF-α),Interleukin-2,6,17(IL-2,6,17)were lower than those in the control group(P<0.05);IL-10 was higher than that in the control group(P<0.05).In the two groups,there was no statistical significance in the incidence of adverse reactions and the recurrence rate in the first and the third month after treatment,respectively(P>0.05);the recurrence rate in the observation group was lower than that in the control group(P>0.05).The number of low-risk cases and high-risk cases in the observation group after treatment were less than that in the control group(P<0.05),that is,the negative conversion rate of low-risk and high-risk patients in the observation group after treatment were higher than those in the control group(P<0.05).Conclusion CAI′s gynecological Xiaoyu prescription combined with recombinant human interferon can reduce the syndrome score in patients with cervical HPV infection,help reduce the level of inflammatory factors,reduce the recurrence rate of patients after treatment,and

关 键 词：药物毒性 人乳头瘤病毒 蔡氏妇科消淤方 重组人干扰素 炎症因子 

分 类 号：R737.33[医药卫生—肿瘤]